FindTrial
Sign In

Yoga therapy for depression

Effect of Yoga therapy on Peripheral Blood Mononuclear Cell (PBMC) response to stress in patients with Depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/11/010446
Enrollment
22
Registered
2017-11-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate

Interventions

Intervention1: yoga therapy: yoga therapy with validated yoga module for depression for 2 weeks followed by home practice for 3 months Control Intervention1: NIL: NIL

Sponsors

NIMHANS Integrated Centre for Yoga NICY Department of Psychiatry NIMHANS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. Subjects with DSM IV-TR clinical diagnosis of Major depressive disorder. 2. Severity of depression- mild to moderate. 3. Drug-free for >= 6 months. 4. Age from 18 â?? 60 years 5. Both sexes 6. Patients who opt for yoga therapy as the primary treatment. 7. Yoga-naive subjects (i.e., the participant should not have participated in more than 4 yoga sessions in the past 2 years and not more than 1 session in the past month)

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1. Co-morbid substance abuse (excluding nicotine dependence), psychosis, suicidal and self-injurious behaviour, mental retardation, any other DSM IV-TR anxiety disorders, OCD and related disorders. 2. Severe depression with catatonic symptoms, suicidal risk (suicidal score >3) or severe psychomotor retardation, requiring in-patient care or electroconvulsive therapy(ECT) 3. On antidepressant medication. 4. Bipolar depression. 5. Currently pregnant or lactating. 6. Subjects with severe physical ailments like general medical conditions like coronary artery disease, fracture, seizure disorders, autoimmune disorders, chronic fever and those on treatment with immune-modulating agents. 7. Patients not opting for yoga therapy as primary treatment.

Design outcomes

Primary

MeasureTime frame
Levels of Interleukin 1B (IL-1B), IL-6, Tumor Necrosis Factor a (TNFa) in Peripheral Blood Mononuclear Cells (PBMCs)Timepoint: Baseline 3 months—

Secondary

MeasureTime frame
Brain Derived Neurotrophic Factor (BDNF) levels in serum Hamilton Depression Rating Scale (HDRS) score Timepoint: Baseline 3 months—

Countries

India

Contacts

Public ContactAditi Devi N

National Institute of Mental Health and Neurosciences (NIMHANS)

ssv.nimhans@gmail.com080-26995253

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026